DK2812011T3 - Differentiering ex vivo af nk-celler fra cd34+ hæmatopoietiske celler - Google Patents

Differentiering ex vivo af nk-celler fra cd34+ hæmatopoietiske celler Download PDF

Info

Publication number
DK2812011T3
DK2812011T3 DK13709575.8T DK13709575T DK2812011T3 DK 2812011 T3 DK2812011 T3 DK 2812011T3 DK 13709575 T DK13709575 T DK 13709575T DK 2812011 T3 DK2812011 T3 DK 2812011T3
Authority
DK
Denmark
Prior art keywords
cells
differentizing
vivo
hematopoietic
hematopoietic cells
Prior art date
Application number
DK13709575.8T
Other languages
English (en)
Inventor
Jan Spanholtz
Harmen Dolstra
Original Assignee
Glycostem Therapeutics B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycostem Therapeutics B V filed Critical Glycostem Therapeutics B V
Application granted granted Critical
Publication of DK2812011T3 publication Critical patent/DK2812011T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4613—Natural-killer cells [NK or NK-T]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/145—Thrombopoietin [TPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/21—Chemokines, e.g. MIP-1, MIP-2, RANTES, MCP, PF-4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2306—Interleukin-6 (IL-6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2312—Interleukin-12 (IL-12)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/90—Polysaccharides
    • C12N2501/91—Heparin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK13709575.8T 2012-02-08 2013-02-07 Differentiering ex vivo af nk-celler fra cd34+ hæmatopoietiske celler DK2812011T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12154554 2012-02-08
PCT/NL2013/050073 WO2013119118A1 (en) 2012-02-08 2013-02-07 Ex vivo nk cell differentiation from cd34+ hematopoietic cells

Publications (1)

Publication Number Publication Date
DK2812011T3 true DK2812011T3 (da) 2020-02-24

Family

ID=47884461

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13709575.8T DK2812011T3 (da) 2012-02-08 2013-02-07 Differentiering ex vivo af nk-celler fra cd34+ hæmatopoietiske celler

Country Status (7)

Country Link
US (3) US20150010583A1 (da)
EP (1) EP2812011B1 (da)
CA (1) CA2864283C (da)
DK (1) DK2812011T3 (da)
ES (1) ES2771248T3 (da)
PL (1) PL2812011T3 (da)
WO (1) WO2013119118A1 (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2972662A1 (en) * 2014-12-31 2016-07-07 Anthrogenesis Corporation Natural killer cells and uses thereof
WO2017042393A1 (en) * 2015-09-11 2017-03-16 Emercell Sas Pooled nk cells from umbilical cord blood associated with antibodies and their uses for the treatment of disease
EP3350316B1 (en) * 2015-09-15 2024-05-08 Stichting Radboud universitair medisch centrum IMPROVED METHOD FOR EX VIVO EXPANSION CD34+HSPCs INTO NK CELLS USING AN ARYL HYDROCARBON RECEPTOR ANTAGONIST
TW201732037A (zh) 2015-10-15 2017-09-16 安瑟吉納西斯公司 自然殺手細胞及ilc3細胞及其用途
SG11201809858RA (en) * 2016-05-07 2018-12-28 Celularity Inc Methods of treating acute myeloid leukemia and multiple myeloma using natural killer cells
IT201600121081A1 (it) * 2016-11-29 2018-05-29 Fond Ri Med Immunoterapia NK-mediata e usi di essa
JP6647240B2 (ja) * 2017-05-12 2020-02-14 米満　吉和 高活性ｎｋ細胞、およびその利用
IL276365B2 (en) 2018-02-01 2023-10-01 Nkmax Co Ltd A method for the production of natural killer cells and a preparation for cancer treatment
CN108315299A (zh) * 2018-02-13 2018-07-24 南京支云松生物科技有限公司 一种即用型异体nk细胞库网络储运应用***
CN112204133B (zh) * 2018-05-30 2024-04-19 格雷克斯迪姆医疗私人有限公司 Car nk细胞
JP2022514393A (ja) * 2018-12-21 2022-02-10 ステムセル テクノロジーズ カナダ インコーポレイテッド ナチュラルキラー細胞に分化させるための培地および方法
CN113166726A (zh) 2019-07-08 2021-07-23 南克维斯特公司 单核细胞源性nk细胞
US11453862B2 (en) 2019-07-08 2022-09-27 Immunitybio, Inc. Mononuclear cell derived NK cells
US20220249567A1 (en) * 2019-07-22 2022-08-11 Glycostem Therapeutics B.V. Low density cell culture
WO2021107779A1 (en) * 2019-11-28 2021-06-03 Glycostem Therapeutics B.V. Method for obtaining car-nk cells
US11591381B2 (en) 2020-11-30 2023-02-28 Crispr Therapeutics Ag Gene-edited natural killer cells
EP4271798A1 (en) 2020-12-30 2023-11-08 CRISPR Therapeutics AG Compositions and methods for differentiating stem cells into nk cells
CN113416700B (zh) * 2021-07-09 2023-04-11 天晴干细胞股份有限公司 一种高效的因子分泌型nk细胞扩增方法及其应用
KR102504039B1 (ko) * 2022-10-25 2023-03-02 오정훈 자연살해세포 증식에 효과적인 배양 방법 및 이의 용도

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006004592A2 (en) * 2004-05-28 2006-01-12 Mayo Foundation For Medical Education And Research Methods for autologous stem cell transplantation
WO2006102209A2 (en) * 2005-03-18 2006-09-28 The Ohio State University Research Foundation Cd34(+) cells and their methods of use
PT1941027E (pt) * 2005-09-28 2014-10-09 Ipd Therapeutics B V Métodos e meios para proliferação de células estaminais e subsequente geração e expansão de células progenitoras, bem como produção de células efectoras como produtos terapêuticos clínicos
DK2142642T3 (da) * 2007-03-27 2017-09-11 Ipd-Therapeutics B V Fremgangsmåder og middel til stamcelleproliferation og efterfølgende generering og ekspansion af progenitorceller, såvel som produktion af effektorceller som kliniske terapeutika

Also Published As

Publication number Publication date
CA2864283C (en) 2020-11-03
EP2812011B1 (en) 2020-01-15
CA2864283A1 (en) 2013-08-15
US10822589B2 (en) 2020-11-03
ES2771248T3 (es) 2020-07-06
PL2812011T3 (pl) 2020-06-29
US20210054338A1 (en) 2021-02-25
US20150010583A1 (en) 2015-01-08
WO2013119118A1 (en) 2013-08-15
US20180044636A1 (en) 2018-02-15
EP2812011A1 (en) 2014-12-17

Similar Documents

Publication Publication Date Title
DK2812011T3 (da) Differentiering ex vivo af nk-celler fra cd34+ hæmatopoietiske celler
SMT201500263B (it) Composizioni solide
HK1207882A1 (en) T cell receptor-deficient cell compositions t t
EP2939206A4 (en) MANAGEMENT OF E-MAILS WITH PAYMENTS
FR2950069B1 (fr) Utilisation de compositions ternaires
DK2640893T4 (da) Sammensætninger
PT3023788T (pt) Composições de neoantigénios específicos de tumor para utilização no tratamento de tumores
DK3354747T3 (da) Ikke-invasiv bestemmelse af tumormethylom fra plasma
DK2911506T3 (da) Driftreducerende sammensætninger
BR112014020543A8 (pt) composições de ração e métodos de utilização das mesmas
DK3418396T3 (da) Vurdering af cellulær signalvejsaktivitet under anvendelse af probabilistisk modellering af målgenekspression
BR112013017183A2 (pt) composições de bepostatina
CO6930368A2 (es) Composiciones de yodo-povidona estable
DK2931970T4 (da) Cellulose-afledte sammensætninger
DK3156056T3 (da) Farmaceutiske sammensætninger der består af sorbitanestere
DK2528602T4 (da) Formuleringer af bendamustin
CO6980141A1 (es) Compuestos y composiciones de poliglicerilo catónicos
DK2633006T3 (da) Fremstilling af fornybart bio-destillat
CO6950470A2 (es) Formulaciones derivadas de decitabina
DK2822568T3 (da) Anvendelser af caseinsammensætninger
ITTO20110268A1 (it) Composizione di maquillage.
DK2931842T3 (da) Omdannelse af triacylglyceridholdige olier
FR2987600B1 (fr) Nacelle aplatie de turboreacteur
DE112011104051A5 (de) Kombi-Radsatzpresse
HK1198660A1 (en) Replenishing compositions and methods of replenishing pretreatment compositions